/
SNN
$28.81-$1.47 (-4.85%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.7B
423M shares
52-week range
$28.56 – $38.79
2% from low
Exchange
NYSE
ADRC
Borrow rate
4.32%
Moderate
Price (6 mo)
Loading chart…
Change$-15.06
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.90B | $5.14B | $4.56B | $5.21B | $5.21B | $5.55B | $5.81B | $6.18B |
| Cost of revenue | $1.30B | $1.34B | $1.40B | $1.54B | $1.54B | $1.73B | $1.76B | $1.98B |
| Gross profit | $3.61B | $3.80B | $3.16B | $3.67B | $3.67B | $3.82B | $4.05B | $4.20B |
| Gross margin | 73.5% | 74.0% | 69.4% | 70.4% | 70.5% | 68.8% | 69.6% | 68.0% |
| R&D | $246.0M | $292.0M | $307.0M | $356.0M | $345.0M | $299.0M | $289.0M | $296.7M |
| Operating income | $863.0M | $815.0M | $295.0M | $593.0M | $315.0M | $425.0M | $657.0M | $1.01B |
| EBITDA | $1.29B | $1.34B | $866.0M | $1.24B | $874.0M | $956.0M | $1.24B | $1.58B |
| Net income | $663.0M | $600.0M | $448.0M | $524.0M | $223.0M | $263.0M | $412.0M | $626.5M |
| Net margin | 13.5% | 11.7% | 9.8% | 10.1% | 4.3% | 4.7% | 7.1% | 10.1% |
| EPS (diluted) | 1.52 | 1.36 | 1.02 | 1.20 | 0.50 | 1.20 | 0.94 | 1.44 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.6B | $2.21 | $2.18–$2.23 | 3 |
| 2027 | $6.9B | $2.46 | $2.43–$2.48 | 3 |
| 2028 | $7.3B | $2.74 | $2.71–$2.76 | 1 |
| 2029 | $7.8B | $2.97 | $2.94–$3.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$30.35
Price
$28.81
Implied upside
+5%
Peer comparison
Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
www.smith-nephew.com- Employees
- 16,988
- IPO / List date
- Nov 16, 1999
Held by traders on TradeandTell
No one on the platform currently holds SNN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 275,461 | $8.8M |
| Renaissance Technologiesas of 2025-06-30 | 96,250 | $2.9M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 5.32% ($1.53/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-27 | $0.4820 | 2026-05-27 |
| 2025-10-03 | $0.3000 | 2025-11-07 |
| 2025-03-28 | $0.4620 | 2025-05-28 |
| 2024-10-04 | $0.2880 | 2024-11-08 |
| 2024-04-01 | $0.4620 | 2024-05-22 |
| 2023-10-05 | $0.2880 | 2023-11-01 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2014-10-15 | 2.5-for-1 |
| 2003-12-16 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded SNN yet.
